Overview

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Status:
Terminated

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.

Phase:

N/A

Details

Lead Sponsor:

Zhi-Hong Liu, M.D.

Treatments:

Irbesartan
Sevelamer